Myriad Genetics Receives FDA Approval for Companion Diagnostic Test for GSK's Zejula in Ovarian Cancer Patients

Myriad Genetics' MyChoice CDx Test has received FDA approval as a companion diagnostic for Zejula (niraparib) in ovarian cancer. The test determines homologous recombination deficiency status, enabling precise identification of patients who may benefit from PARP inhibitors. This approval reinforces Myriad's leadership in ovarian cancer diagnostics and underscores the clinical importance of comprehensive HRD testing.